Common toxicities of mammalian target of rapamycin inhibitors
- PMID: 21499766
- DOI: 10.1007/s11523-011-0174-9
Common toxicities of mammalian target of rapamycin inhibitors
Abstract
The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.
Similar articles
-
Mammalian target of rapamycin: biological function and target for novel anticancer agents.Am J Health Syst Pharm. 2010 Dec 15;67(24):2095-106. doi: 10.2146/ajhp100020. Am J Health Syst Pharm. 2010. PMID: 21116000 Review.
-
Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.Oral Dis. 2018 Mar;24(1-2):144-171. doi: 10.1111/odi.12795. Oral Dis. 2018. PMID: 29480626 Review.
-
Everolimus: side effect profile and management of toxicities in breast cancer.Breast Cancer Res Treat. 2013 Aug;140(3):453-62. doi: 10.1007/s10549-013-2630-y. Epub 2013 Aug 2. Breast Cancer Res Treat. 2013. PMID: 23907751 Review.
-
Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.Curr Med Res Opin. 2014 Jan;30(1):67-74. doi: 10.1185/03007995.2013.844116. Epub 2013 Oct 4. Curr Med Res Opin. 2014. PMID: 24028709 Review.
-
Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.J Clin Pharmacol. 2015 Apr;55(4):368-76. doi: 10.1002/jcph.428. Epub 2014 Dec 30. J Clin Pharmacol. 2015. PMID: 25402866 Review.
Cited by
-
FAM120A couples SREBP-dependent transcription and splicing of lipogenesis enzymes downstream of mTORC1.Mol Cell. 2023 Aug 17;83(16):3010-3026.e8. doi: 10.1016/j.molcel.2023.07.017. Mol Cell. 2023. PMID: 37595559 Free PMC article.
-
Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer.Pharmaceuticals (Basel). 2023 Jul 14;16(7):1004. doi: 10.3390/ph16071004. Pharmaceuticals (Basel). 2023. PMID: 37513916 Free PMC article. Review.
-
A Novel Bioactive Peptide, T14, Selectively Activates mTORC1 Signalling: Therapeutic Implications for Neurodegeneration and Other Rapamycin-Sensitive Applications.Int J Mol Sci. 2023 Jun 9;24(12):9961. doi: 10.3390/ijms24129961. Int J Mol Sci. 2023. PMID: 37373106 Free PMC article.
-
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.Cancer Res. 2023 Oct 2;83(19):3252-3263. doi: 10.1158/0008-5472.CAN-23-0282. Cancer Res. 2023. PMID: 37339176 Free PMC article.
-
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).Rheumatol Ther. 2023 Aug;10(4):825-847. doi: 10.1007/s40744-023-00546-0. Epub 2023 Apr 17. Rheumatol Ther. 2023. PMID: 37069364 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous